Daratumumab in the Management of Red Cell Aplasia Following Allogeneic Hematopoietic Stem Cell Transplantation
European Journal of Haematology · 2025
DOI: 10.1111/ejh.14341 ↗Kurz gefasst
Fallbericht in der Zeitschrift European Journal of Haematology, 2025. Verfasst von Nihar Desai und 5 weiteren Autor:innen. Beteiligte Einrichtung: Hans Messner Allogeneic Blood and Marrow Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Canada. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Red-Cell Aplasia, Pure, Antibodies, Monoclonal, Transplantation, Homologous. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 13 Literaturangaben.
Abstract (Originalsprache)
Pure red cell aplasia (PRCA) is a rare but significant complication following major ABO‐incompatible allogeneic hematopoietic stem cell transplantation (HSCT). The persistence of recipient B lymphocytes producing anti‐donor isohemagglutinins leads to reticulocytopenia and anemia, often resulting in transfusion dependence. Current treatment options for post‐HSCT PRCA are limited and frequently yield suboptimal responses, complicating patient management. Herein, we report three cases of post‐HSCT PRCA successfully managed with daratumumab, a monoclonal antibody targeting CD38‐expressing plasma cells. All patients demonstrated rapid reticulocyte recovery and transfusion independence after daratumumab treatment, despite prior treatment failures. These findings suggest that daratumumab may provide a more effective therapeutic approach, with a favorable safety profile compared to traditional therapies. Given its demonstrated efficacy and safety, daratumumab warrants consideration as a first‐line treatment for post‐HSCT PRCA, potentially improving patient quality of life and reducing transfusion‐related complications. Further studies should explore optimal dosing and long‐term outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hans Messner Allogeneic Blood and Marrow Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Canada.
- Temerty faculty of Medicine, University of Toronto, Toronto, Canada.
ORCID-Profile: Nihar Desai, Auro Viswabandya, Dennis Dong Hwan Kim, Jeffrey H Lipton, Jonas Mattsson, Arjun Datt Law
Zitieren
APA
Desai, N., Viswabandya, A., Kim, D. D. H., Lipton, J. H., Mattsson, J., & Law, A. D. (2025). Daratumumab in the Management of Red Cell Aplasia Following Allogeneic Hematopoietic Stem Cell Transplantation. European Journal of Haematology. https://doi.org/10.1111/ejh.14341
Vancouver
Desai N, Viswabandya A, Kim DDH, Lipton JH, Mattsson J, Law AD. Daratumumab in the Management of Red Cell Aplasia Following Allogeneic Hematopoietic Stem Cell Transplantation. European Journal of Haematology. 2025. doi:10.1111/ejh.14341
BibTeX
@article{Desai2025,
author = {Desai, Nihar and Viswabandya, Auro and Kim, Dennis Dong Hwan and Lipton, Jeffrey H and Mattsson, Jonas and Law, Arjun Datt},
title = {Daratumumab in the Management of Red Cell Aplasia Following Allogeneic Hematopoietic Stem Cell Transplantation},
journal = {European Journal of Haematology},
year = {2025},
doi = {10.1111/ejh.14341}
}
EUVIMED